Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A procedure for developing risk-based reference doses.

David W Gaylor1, Ralph L Kodell

  • 1Sciences International, Inc., Alexandria, VA 22314, USA.

Regulatory Toxicology and Pharmacology : RTP
|June 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is premarket identification of hepatotoxic drugs and sensitive patients possible based on high-dimensional 'omic data?

Personalized medicine·2018
Same author

Novel Use of Proteomic Profiles in a Convex-Hull Ensemble Classifier to Predict Gynecological Cancer Patients' Susceptibility to Gastrointestinal Mucositis as Side Effect of Radiation Therapy.

Journal of proteomics & bioinformatics·2015
Same author

Immune Function and Muscle Adaptations to Resistance exercise in Older Adults: Study Protocol for a Randomized Controlled Trial of a Nutritional Supplement.

Trials·2015
Same author

Effectiveness of methylcobalamin and folinic Acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status.

Autism research and treatment·2013
Same author

Practical advice on calculating confidence intervals for radioprotection effects and reducing animal numbers in radiation countermeasure experiments.

Radiation research·2013
Same author

A diversity index for model space selection in the estimation of benchmark and infectious doses via model averaging.

Risk analysis : an official publication of the Society for Risk Analysis·2013
Same journal

The NTP Chronic Inhalation Study Does Not Support an Inherent Lung Cancer Hazard of Talc: Implications of Lung Particle Overload and Maximum Tolerated Dose.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Consideration of Carcinogenicity and Mode of Action Information by an Independent Expert Panel to Support Derivation of No-Significant-Risk-Level Values for Vinyl Acetate Monomer.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Which carcinogenicity study should I use? Automated identification of reliable studies.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Adoption of artificial intelligence in drug review across the lifecycle: Transformation of regulatory decision-making.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Cardiovascular outcomes following intrauterine and lactational exposure to cyantraniliprole in male Wistar rats.

Regulatory toxicology and pharmacology : RTP·2026
Same journal

Pesticide residue and mycotoxin occurrence in apples and their impact on human health in Morocco.

Regulatory toxicology and pharmacology : RTP·2026
See all related articles

Establishing risk-based reference doses (RfDs) uses benchmark doses (BMDs) to account for interindividual sensitivity, improving toxic substance exposure limits for public health protection.

Area of Science:

  • Toxicology
  • Risk Assessment
  • Environmental Health

Background:

  • Reference doses (RfDs) traditionally use NOAEL/LOAEL, which may not fully capture population variability.
  • Uncertainty factors (UFs) are applied to RfDs, including a default UF of 10 for interindividual sensitivity.
  • Existing methods may not adequately address the range of human sensitivity to toxic substances.

Purpose of the Study:

  • To propose a method for calculating risk-based RfDs using benchmark doses (BMDs).
  • To incorporate estimates of interindividual sensitivity to refine uncertainty factors.
  • To improve the accuracy of RfD estimations for better public health protection.

Main Methods:

  • Replacing NOAEL/LOAEL with BMDs associated with a specific risk level.

Related Experiment Videos

  • Utilizing population variability data, often log-normal distributions, to estimate interindividual sensitivity.
  • Calculating a specific uncertainty factor for interindividual variation based on the standard deviation of sensitivity.

    • Main Results:

    • A standard deviation of 1.7 for log(e) individual sensitivity (UF ≈ 5.5) can limit risk to 1 in 10,000 when using a 10% BMD.
    • A more typical standard deviation of 1.2 (UF ≈ 20) offers improved risk management compared to default UFs.
    • Risk estimates at the RfD can be substantially lowered with more precise estimates of interindividual variability.

    Conclusions:

    • Risk-based RfDs calculated with BMDs and specific interindividual sensitivity data provide more refined exposure guidelines.
    • This approach allows for the estimation of RfDs with a specified level of risk, enhancing safety.
    • Further refinement is possible by using chemical- or endpoint-specific variability data, though animal-to-human extrapolation UFs remain necessary.